SynthesisFrontiers in psychiatry2026
Suicide and psychiatric disorders associated with amphetamine type stimulant use: a systematic review and meta-analysis.
Synthesis in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study reviews the literature to determine the prevalence and nature of suicidality and psychiatric comorbidity in individuals with amphetamine-type stimulant (ATS) use to inform targeted interventions. Methods: We searched the Web of Science, PubMed, Scopus, and Cochrane Library databases for relevant papers published until March 2025. Two independent reviewers collected the following data: baseline information, outcomes, prevalence of suicidality, psychiatric disorders, employment status, marital status, additional substances used, age at onset of use, and duration of use. Results: We collected 2,969 records after excluding 2,072 duplicates. Thorough screening yielded 70 entries eligible for inclusion. Our analysis revealed prevalence rates of 26% for depression, 22% for hallucinations, 20% for suicidality, 23% for suicidal ideation, 17% for suicide attempts, and 13% for deaths by suicide. Additionally, 38% of individuals who use ATS also used multiple other substances concurrently, and the mean duration of ATS use was estimated to be 5.13 years. The total pooled sample size across all included studies was 311,669 persons. Conclusion: This systematic review highlights the high prevalence of psychiatric conditions, including depression, hallucinations, and suicidality, frequently co-occurring with concurrent use of multiple substances and psychiatric disorders. These findings represent prevalence rates within the ATS-using population, and no comparison with non-ATS populations was performed; therefore, they do not imply an excess or attributable risk. The results underscore the critical need for integrated screening and service-planning guidance in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.